Vertical Payers: “Highly Integrated” by 2026

Article

Vertical Payers: “Highly Integrated” by 2026

July 18, 2024
Authors
Topics

Welcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.

Vertical stacked puzzle pieces

HMP Market Access Insights (MAI) has been reporting on vertical payer integration since the inception of our primary payer research arm in 2022. Every year, we hear how these national players intend to further enhance their internal integration regarding business operations, policy decision making, and data sharing. However, this year we see a greater than normal ‘bump’ for what the future holds. In short, vertical payers anticipate a very high degree of integration within these critically important areas over the next few years (Figure).

Graph


Figure. Percentage of 2024 Vertical Payer Respondents Selecting “High” or “Full” Integration (N = 25).
Source: HMP Market Access Insights 2024 Payer Annual Oncology Trend Report.

  • Manufacturer contracting—greatest increase: The most anticipated area of increased integration is in contracting with manufacturers for rebates and discounts. Related data also show a 48% increase in the number of vertical payer respondents anticipating their level of integration in this area going from “None/Little/Moderate” to “High/Full.”
  • Internal data sharing—empowering payer leverage: Often related to manufacturer contracting, our respondents expect much greater integrated internal sharing of drug utilization data. Through interviews, we also know that aggregated drug-level clinical outcomes, adherence, and other data will be analyzed across entities, too.
  • Health plan vs pharmacy benefit manager (PBM): Within each vertical payer organization, respondents from the PBM entity tend to anticipate lower levels of integration in each of the 4 areas investigated than respondents from the health plan entity.

We look forward to sharing additional insights later this summer when we release our full 2024 Payer Annual Trend Report, part of our suite of Oncology Customer Insights offerings!

Be sure to check out the other reports from HMP MAI:

In the interim, please feel free to reach out to Sara Stewart with any questions you may have!

The Latest

Our 2024-2025 Oncology Clinical Pathways Report, set for release in December, will provide insights into the most impactful pathways and key factors manufacturers should assess as the oncology pathways landscape continues to evolve.
Article
Unlocking Oncology Pathway Impact: Beyond Lives Covered to Real Prescribing Influence

As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.

Daniel Buchenberger
Podcast
Community Oncology Practice Economics - Podcast Part 3 of 3

In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.

Lee Blansett
Bispecific Antibodies: A Balancing Act of Promise and Complexity
Article
Bispecific Antibodies: A Balancing Act of Promise and Complexity

Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.

Chris Van Denburg